|
Early Sedation with Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients A Prospective, Multi-Centre, Double-Blind, Randomized, Controlled Trial. SPICE IV
|
Ongoing
|
DEXMEDETOMIDINE
|
4
|
SCT21R/006/04
|
King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
VICTORION REAL: An international prospective Real-world study to evaluate the Effectiveness and Adherence of incLisiran plus standard of care lipid-lowering therapy compared to standard of care therapy alone in patients with primary hypercholesterolemia or mixed dyslipidemia
|
Ongoing
|
Inclisiran
|
4
|
CKJX839A12
|
Saud Al-Babtain Cardiac Center (Dammam) , King Salman Armed Forces Hospital(Tabuk) , King Fahd Armed Forces Hospital (Jeddah) , Dr. Sulaiman Al-Habib Medical Group Rayan (Riyadh),King Faisal Specialist Hospital and Research Center (Jeddah), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), International Medical Center (Jeddah)
|
|
The effect of novel D3 use as a mouthwash in COVID-19 patients
|
Rejected
|
D3 mouthwash
|
4
|
2022-32
|
King Faisal Specialist Hospital and Research Center (Jeddah)
|
|
O-SEMA-Fast: A research study to understand how oral semaglutide works in people with type 2 diabetes who plan to fast during Ramadan in the United Arab Emirates, Saudi Arabia, and Kuwait
|
Ongoing
|
Semaglutide
|
4
|
NN9924-757
|
Almoosa Specialist Hospital (Alahsa)
|
|
Study on Clinical Use of EVUSHELD (AZD7442) as Pre-exposure Prophylaxis in the Real-world Setting – A Multi-centre Observational Prospective Study to Determine the Utilisation and Clinical Outcomes of EVUSHELD in Middle East and Africa
|
Ongoing
|
EVUSHELD
|
4
|
D8851R0000
|
King Saud Medical City (Riyadh)
|
|
A REGISTRY TO COLLECT CHARACTERISTICS AND OUTCOMES FROM PATIENTS WITH SOLID TUMORSPROFILED WITH A NEXT-GENERATION SEQUENCINGTEST (WAYFIND-R)
|
Ongoing
|
NA
|
4
|
MX39897
|
King Abdulaziz Medical City NG (Riyadh)
|
|
Real-World Experience of Upadacitinib in Moderate to Severe Atopic Dermatitis
|
Ongoing
|
Upadacitinib (Rinvoq)
|
4
|
H23-107
|
King Faisal General Hospital (Makkah), Mohammed Dossary Hospital - Al Khobar, King Fahad Central Hospital (Jazan), East Jeddah General Hospital, Hira Hospital (Makkah) , Aseer Central Hospital (Abha)
|
|
Articaine efficacy and safety for 3 years old children: A Clinical Randomized Control Trial.
|
Ongoing
|
Articaine
|
3
|
607-43-7809
|
Qassim Regional Dental Center
|
|
An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment.
|
Ongoing
|
ABL001 (Asciminib), Imatinib, Nilotinib, Bosutinib
|
3
|
CABL001A2001B
|
King Faisal Specialist Hospital and Research Center (Riyadh)
|
|
Palbociclib Combinations in HR+/HER2- Metastatic Breast Cancer Patients: A Non-Interventional Prospective Study on the Treatment Patterns & Clinical Outcomes in Africa Middle East (PRECIOUS)
|
Ongoing
|
PALBOCICLIB
|
4
|
A5481150
|
King Fahad Specialist Hospital (Dammam) , King Abdulaziz Medical City NG (Riyadh) , King Khalid University Hospital (Riyadh)
|
